Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TOPICS／Daiichi Sankyo Introduces Stock Compensation-Type Stock Option Plan
March 3, 2008
- NPhA Frustrated with Maintenance of 2 Different Dispensing Fees
March 3, 2008
- DSP Plans to Market Lurasidone Independently in US
February 25, 2008
- Novo Nordisk Discontinues Transpulmonary Insulin Project AERx
February 25, 2008
- Dr Karasawa Will Stand for Reelection JMA President
February 25, 2008
- Taisho Initiates TOB for Biofermin
February 25, 2008
- CV Risk Lower with Lipitor than with Simvastatin: Pfizer
February 25, 2008
- One in 3 Physicians Recognizes Diovan Advertisements
February 25, 2008
- Meeting Market Needs with Original Drugs and Generics: Mochida
February 25, 2008
- Mevalotin Reduces Risk of CV Events in Postmenopausal Women
February 25, 2008
- FUJIFILM Embarks on Drug Business in Earnest by Acquiring Toyama Chemical
February 25, 2008
- Baxter Has Much Room for Growth in Japan: President Kawabata
February 25, 2008
- R&D NEWS IN BRIEF
February 25, 2008
- Korosho to Meet Concerned Parties to Improve Drug Distribution Practices
February 25, 2008
- OPINION／The Hottest Jobs in 2008 Revealed
February 25, 2008
- SSP to Promote Core Brand Strategy Based on 8 Products
February 25, 2008
- MEDICAL DEVICE NEWS IN BRIEF
February 25, 2008
- AZ Trains District Managers to Enhance Its Sales Forces
February 25, 2008
- Mediceo Paltac to Deal with Generics in Earnest
February 25, 2008
- Novartis to Launch Galvus in Europe
February 25, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…